Provention Bio Analysis
Provention Bio holds a debt-to-equity ratio of 0.008. With a high degree of financial leverage come high-interest payments, which usually reduce Provention Bio's Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Provention Bio's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Provention Bio's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Provention Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Provention Bio's stakeholders.
For most companies, including Provention Bio, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Provention Bio, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Provention Bio's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Provention Bio's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Provention Bio is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Provention Bio to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Provention Bio is said to be less leveraged. If creditors hold a majority of Provention Bio's assets, the Company is said to be highly leveraged.
Provention Bio is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Provention Bio delisted stock analysis is to determine its intrinsic value, which is an estimate of what Provention Bio is worth, separate from its market price. There are two main types of Provention Bio's stock analysis: fundamental analysis and technical analysis.
The Provention Bio stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Provention Bio's ongoing operational relationships across important fundamental and technical indicators.
Provention |
Provention Stock Analysis Notes
About 53.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.52. Provention Bio had not issued any dividends in recent years. Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey. Provention Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people. To find out more about Provention Bio contact the company at 908 336 0360 or learn more at https://www.proventionbio.com.Provention Bio Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Provention Bio's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Provention Bio or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Provention Bio is not yet fully synchronised with the market data | |
| Provention Bio has some characteristics of a very speculative penny stock | |
| Provention Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 12.89 M. Net Loss for the year was (113.56 M) with loss before overhead, payroll, taxes, and interest of (63.42 M). | |
| Provention Bio currently holds about 84.52 M in cash with (75.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04. |
Provention Bio Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Provention Bio previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of May 2023 Upcoming Quarterly Report | View | |
| 3rd of August 2023 Next Financial Report | View | |
| 31st of March 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 31st of December 2022 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Provention Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.38 B.Provention Bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Provention Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Provention Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Provention Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sessa Capital Master Lp over a year ago Disposition pursuant to a tender of shares in a change of control transaction by Sessa Capital Master Lp of Provention Bio | ||
Sessa Capital Master Lp over a year ago Provention Bio exotic insider transaction detected | ||
Sessa Capital Master Lp over a year ago Exercise of in-the-money or at-the-money derivative position by Sessa Capital Master Lp of 8879023 shares of Provention Bio | ||
Francisco Leon over a year ago Bona fide gift to Francisco Leon of 1500000 shares of Provention Bio subject to Section 16 |
Provention Bio Outstanding Bonds
Provention Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Provention Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Provention bonds can be classified according to their maturity, which is the date when Provention Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US743756AB40 Corp BondUS743756AB40 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Provention Bio Debt to Cash Allocation
As Provention Bio follows its natural business cycle, the capital allocation decisions will not magically go away. Provention Bio's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Provention Bio currently holds 23.47 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Provention Bio has a current ratio of 3.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Provention Bio's use of debt, we should always consider it together with its cash and equity.Provention Bio Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Provention Bio's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Provention Bio, which in turn will lower the firm's financial flexibility.Provention Bio Corporate Bonds Issued
Most Provention bonds can be classified according to their maturity, which is the date when Provention Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Provention Bio to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Diagnostics Now
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings |
| All Next | Launch Module |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Provention Stock
If you are still planning to invest in Provention Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provention Bio's history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |